{
    "pmcid": "9676808",
    "qa_pairs": {
        "What computational techniques were used to optimize nanobodies for binding to the RBD of various SARS-CoV-2 variants?": [
            "Homology modeling, docking studies, and alanine scanning mutagenesis",
            "Cryo-electron microscopy and X-ray crystallography",
            "Flow cytometry and surface plasmon resonance",
            "Mass spectrometry and nuclear magnetic resonance"
        ],
        "What is the dual mechanism of action of the biparatopic nanobody-peptide conjugate (NPC) described in the study?": [
            "Blocking both the viral RBD and the host ACE2 receptor",
            "Inhibiting viral replication and enhancing immune cell activation",
            "Neutralizing viral particles and promoting antibody-dependent cellular cytotoxicity",
            "Preventing viral entry and disrupting viral RNA synthesis"
        ],
        "What is the primary target of the nanobodies designed in the study for SARS-CoV-2 therapeutics?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What is the purpose of PEGylation in the nanobody construct described in the study?": [
            "To increase size, reduce renal clearance, and improve stability",
            "To enhance binding affinity to the RBD",
            "To target cryptic epitopes inaccessible to conventional antibodies",
            "To facilitate inhaled delivery of the nanobody"
        ],
        "Which mutation in the receptor-binding domain (RBD) is highlighted for enhancing the virus's ability to bind ACE2 and evade immune responses?": [
            "N501Y",
            "D614G",
            "E484K",
            "P681R"
        ]
    }
}